Urgent.News

What's breaking now, across hundreds of outlets.

Health & Medicine

CG Oncology drug delivers ‘exceptional’ results in key bladder cancer trial

CG’s therapy cretostimogene cut the risk of recurrence by 68% when administered after surgery, far surpassing Wall Street’s expectations and lifting company shares.

We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.

Read the original at biopharmadive.com →

Report a problem with this story

More in Health & Medicine

More from Monday 16 November →